Back to Search
Start Over
Clinical significance of recurrent gastroesophageal junction intestinal metaplasia after endoscopic eradication of Barrett’s esophagus
- Source :
- Gastrointestinal Endoscopy. 93:1250-1257.e3
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
-
Abstract
- Background and Aims After endoscopic eradication of Barrett’s esophagus (BE), recurrence of intestinal metaplasia at the gastroesophageal junction (GEJIM) is common. The clinical significance of this finding is unclear. We assessed whether recurrent GEJIM is associated with increased risk of subsequent dysplasia and whether endoscopic treatment lowers this risk. Methods A retrospective, multicenter, cohort study was performed of treated BE patients who achieved complete eradication of intestinal metaplasia (IM). Postablation follow-up was performed at standard intervals. Recurrent GEJIM was defined as nondysplastic IM on gastroesophageal junction biopsy specimens without endoscopic evidence of BE. Patients were categorized as “never-GEJIM,” “GEJIM-observed,” or “GEJIM-treated.” Endoscopic treatment for recurrent GEJIM was at the endoscopists’ discretion. The primary outcome was dysplasia recurrence. Analyses were performed using log-rank tests and Cox proportional hazards modeling. Results Six hundred thirty-three patients were analyzed; median follow-up was 47 months (interquartile range, 24-69). Most patients (81%) had high-grade dysplasia or intramucosal adenocarcinoma before treatment. Dysplasia recurrence was 2.2% per year. GEJIM-observed patients had the lowest rate of recurrence (.6%/y) followed by GEJIM-treated (2.2%/y) and never-GEJIM (2.6%/y) (log-rank P = .07). In multivariate analyses, compared with never-GEJIM, the risk of dysplasia recurrence was significantly lower in GEJIM-observed patients (adjusted hazard ratio, .19; 95% confidence interval, .05-.81) and not different in GEJIM-treated patients (adjusted hazard ratio, .81; 95% confidence interval, .39-1.67). Older age and longer initial BE length were independently associated with recurrence. Conclusions Recurrent GEJIM after endoscopic eradication of BE was not associated with an increased risk of subsequent dysplasia. Future studies are warranted to determine if observation is appropriate for this finding.
- Subjects :
- medicine.medical_specialty
Esophageal Neoplasms
Gastroenterology
Cohort Studies
Barrett Esophagus
Interquartile range
Internal medicine
medicine
Humans
Radiology, Nuclear Medicine and imaging
Clinical significance
Esophagus
Aged
Retrospective Studies
Metaplasia
business.industry
Proportional hazards model
Hazard ratio
Intestinal metaplasia
medicine.disease
medicine.anatomical_structure
Dysplasia
Barrett's esophagus
Esophagogastric Junction
Esophagoscopy
Neoplasm Recurrence, Local
business
Subjects
Details
- ISSN :
- 00165107
- Volume :
- 93
- Database :
- OpenAIRE
- Journal :
- Gastrointestinal Endoscopy
- Accession number :
- edsair.doi.dedup.....97b4ef7ac01ac4108ec9042178ab553a
- Full Text :
- https://doi.org/10.1016/j.gie.2020.10.027